HOME / PUBLICATIONS /

The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer

Citation:

Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z, Kousidou E, Tzetis M, Kanavakis E, Stravodimos K, Manola KN, Pantelias GE, Scorilas A, Klinakis A. The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer. EMBO Rep 2019;20

Abstract:

Genome-wide studies in tumor cells have indicated that chromatin-modifying proteins are commonly mutated in human cancers. The lysine-specific methyltransferase 2C (KMT2C/MLL3) is a putative tumor suppressor in several epithelia and in myeloid cells. Here, we show that downregulation of KMT2C in bladder cancer cells leads to extensive changes in the epigenetic status and the expression of DNA damage response and DNA repair genes. More specifically, cells with low KMT2C activity are deficient in homologous recombination-mediated double-strand break DNA repair. Consequently, these cells suffer from substantially higher endogenous DNA damage and genomic instability. Finally, these cells seem to rely heavily on PARP1/2 for DNA repair, and treatment with the PARP1/2 inhibitor olaparib leads to synthetic lethality, suggesting that cancer cells with low KMT2C expression are attractive targets for therapies with PARP1/2 inhibitors.

Notes:

Rampias, TheodorosKaragiannis, DimitrisAvgeris, MargaritisPolyzos, AlexanderKokkalis, AntonisKanaki, ZoiKousidou, EvgeniaTzetis, MariaKanavakis, EmmanouilStravodimos, KonstantinosManola, Kalliopi NPantelias, Gabriel EScorilas, AndreasKlinakis, ApostolosengResearch Support, Non-U.S. Gov'tEngland2019/01/23 06:00EMBO Rep. 2019 Mar;20(3). pii: embr.201846821. doi: 10.15252/embr.201846821. Epub 2019 Jan 21.